Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model.
10.7774/cevr.2013.2.2.128
- Author:
Chung Truong NGUYEN
1
;
Seol Hee HONG
;
Thuan Trong UNG
;
Vivek VERMA
;
Soo Young KIM
;
Joon Haeng RHEE
;
Shee Eun LEE
Author Information
1. Clinical Vaccine R&D Center, Chonnam National University, Gwangju, Korea. selee@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Flagellin;
Adjuvant;
Neoplasms;
Vaccines
- MeSH:
Administration, Intranasal;
Animals;
Flagellin;
Humans;
Immunity, Cellular;
Immunity, Mucosal;
Immunization;
Interferon-gamma;
Lymph Nodes;
Lymphocytes;
Mice;
Peptides;
Survival Rate;
Toll-Like Receptor 5;
Ursidae;
Vaccination;
Vaccines;
Vibrio vulnificus
- From:Clinical and Experimental Vaccine Research
2013;2(2):128-134
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Human papillomavirus (HPV) is a significant cause of cervical cancer-related deaths worldwide. Because HPV is a sexually transmitted mucosal pathogen, enhancement of antigen-specific mucosal immune response likely serves good strategy for vaccination. However, mucosal vaccines generally do not induce strong enough immune responses. Previously we proved that a bacterial flagellin, Vibrio vulnificus FlaB, induce strong antigen-specific immune responses by stimulating the Toll-like receptor 5. In this study, we tested whether FlaB could serve as an effective mucosal adjuvant for a peptide-based HPV preventive cancer vaccine. MATERIALS AND METHODS: Mice were intranasally administered with a mixture of FlaB and E6/E7 protective peptides in 5-day interval for a total of two times. Five-days after the last vaccination, cellular immune responses of the vaccinated mice were analyzed. Tumor growth was also observed after a subcutaneous implantation of TC-1 cells bearing E6/E7 antigens. RESULTS: Intranasal administration of the E6/E7 peptide mixture with FlaB elicited a strong antigen-specific cytotoxic T lymphocyte activity and antigen-specific interferon-gamma production from splenocytes and cervical lymph node cells. Furthermore, FlaB, as a mucosal adjuvant, conferred an excellent protection against TC-1 tumor challenge with high survival rates in E6/E7 immunized animals. CONCLUSION: These results indicate that FlaB can be a promising mucosal adjuvant for nasal HPV vaccine development.
